Core Viewpoint - COSCIENS Biopharma Inc. has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited for the commercialization of Macrilen in specific Asian markets, aiming to address the unmet need for growth hormone deficiency diagnostics [1][2][3]. Company Overview - COSCIENS Biopharma Inc. focuses on pharmaceutical therapies, diagnostic products, and natural ingredient solutions, with a diverse portfolio that includes the development of natural, plant-based active ingredients [5]. - The company's lead product, Macrilen (macimorelin), is the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD) [6]. Distribution Agreement Details - The agreement with Wuzhou covers the registration, importation, and commercialization of Macrilen in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan [2]. - The partnership is structured for an initial ten-year term, with Wuzhou committing to a minimum initial order of approximately €800,000 [2]. Strategic Importance - The collaboration is expected to leverage the "Hong Kong and Macao Medicine and Equipment Connect" policy, facilitating expedited market access in the Guangdong-Hong Kong-Macao Greater Bay Area [2]. - The agreement is seen as a key step in COSCIENS' strategy to unlock the global potential of Macrilen and establish sustainable revenue streams [3]. Market Potential - The partnership aims to meet the significant demand for a convenient, oral diagnostic option for patients suspected of AGHD in the dynamic Asian markets [3]. - Wuzhou's expertise in regulatory processes and hospital networks is expected to enhance the approval pathways for Macrilen in the targeted regions [4].
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore